Hence, the expression of CD38+ on CD3+CD8+ cells with or without simultaneous expression of PD1 on CD3+CD4+ cells may be utilized as a biomarker of a fatal outcome in hospitalized patients with COVID-19 [15]. This evidence concerns the gene CD8A and COVID-19.